XTL Biopharma Reports H1 2024 Results, Solar Project Term Sheet
Ticker: XTLB · Form: 6-K · Filed: Dec 30, 2024 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Dec 30, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $430,000, $1,500,000, $1.00, $1.20, $300,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, term-sheet, solar-project
Related Tickers: XTLB
TL;DR
XTLB dropped H1 2024 financials, also inked a solar project deal back in March.
AI Summary
XTL Biopharmaceuticals Ltd. announced its financial results for the six months ended June 30, 2024. The company also noted a binding term sheet entered into on March 20, 2024, with The Society for the Protection of Nature in Israel (SPNI) regarding the "Yotvata" solar energy project.
Why It Matters
This filing provides a financial update for XTL Biopharmaceuticals and details a significant step in their diversification into the solar energy sector through the Yotvata project.
Risk Assessment
Risk Level: medium — The filing contains financial results and a term sheet for a solar project, indicating ongoing business activities and potential diversification, but lacks specific forward-looking financial projections or details on the project's current status.
Key Numbers
- H1 2024 — Six Months Ended June 30, 2024 (Period for which financial results were announced)
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Filer of the report and subject of financial results
- June 30, 2024 (date) — End date for the reported financial period
- March 20, 2024 (date) — Date of the binding term sheet announcement
- The Society for the Protection of Nature in Israel (SPNI) (company) — Counterparty to the binding term sheet
- Yotvata (project) — Name of the solar energy project
FAQ
What were the specific financial results for the six months ended June 30, 2024?
The filing states that XTL Biopharmaceuticals Ltd. announced financial results for the six months ended June 30, 2024, but does not provide the specific figures within this document.
What is the current status of the binding term sheet with SPNI for the Yotvata solar project?
The filing mentions the term sheet was entered into on March 20, 2024, but states that the description of the company's business and operations is as of June 30, 2024, and has not been updated for subsequent events, implying no further details on the project's progress are provided here.
Does this filing include updated financial information beyond June 30, 2024?
No, the filing explicitly states that the information is as of June 30, 2024, and has not been updated for subsequent events.
What is the primary business of XTL Biopharmaceuticals Ltd. as indicated by the SIC code?
The Standard Industrial Classification (SIC) code provided is 2834, which corresponds to Pharmaceutical Preparations.
Where are XTL Biopharmaceuticals Ltd.'s principal executive offices located?
The principal executive offices are located at 26 Ben-Gurion St., Ramat Gan 5112001, Israel.
Filing Stats: 2,524 words · 10 min read · ~8 pages · Grade level 13.9 · Accepted 2024-12-30 17:18:50
Key Financial Figures
- $430,000 — pital of the Company and the payment of $430,000 to the shareholders of Social Proxy (th
- $1,500,000 — itment of an investment of an amount of $1,500,000 through a private placement to be consu
- $1.00 — ts (reflecting a price per each unit of $1.00) consisting of one ADS and one warrant,
- $1.20 — ce into one ADS at an exercise price of $1.20 per warrant. Consummation of the Privat
- $300,000 — ement, through June 2024, we provided a $300,000 loan to Social Proxy. The loan bears an
- $5.8 million — lue of Social Proxy was estimated to be $5.8 million according to third party valuation. 1
- $0.594 million — e 30, 2024 XTL reported approximately $0.594 million in cash and cash equivalents and approx
- $0.99 million — and cash equivalents and approximately $0.99 million in marketable securities as of June 30,
- $1.40 million — urities as of June 30, 2024 compared to $1.40 million in cash and cash equivalents and approx
- $0.60 million — and cash equivalents and approximately $0.60 million in marketable securities as of December
- $0.80 million — 31, 2023. The decrease of approximately $0.80 million since December 31, 2023, in cash and ca
- $12 thousand — the six months ended June 30, 2024 were $12 thousand compared to $19 thousand for the corres
- $19 thousand — 30, 2024 were $12 thousand compared to $19 thousand for the corresponding period in 2023. T
- $7 thousand — ponding period in 2023. The decrease of $7 thousands in research and development expenses c
- $584 thousand — the six months ended June 30, 2024 were $584 thousand compared to $395 thousand for the corre
Filing Documents
- ea022610401-6k_xtlbio.htm (6-K) — 58KB
- 0001213900-24-113540.txt ( ) — 59KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 30, 2024 XTL BIOPHARMACEUTICALS LTD. By: /s/ Shlomo Shalev Shlomo Shalev Chief Executive Officer 7